Samridhi Sharma

Samridhi Sharma

Auto-generated profile, based on publicly available information

Samridhi Sharma

Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2022 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
SSSamridhi Sharma
Samridhi Sharma
TSTing Shen
Ting Shen
NCNitin Chitranshi
Nitin Chitranshi
VGVeer Gupta
Veer Gupta
DBDevaraj Basavarajappa
Devaraj Basavarajappa
Vivek GuptaVivek Gupta
Vivek Gupta
Retinoid X receptors (RXRs) present a subgroup of the nuclear receptor superfamily with particularly high evolutionary conservation of ligand binding domain. The receptor exists in α, β, and γ isotypes that form homo-/heterodimeric complexes with other permissive and non-permissive receptors. While research has identified the biochemical roles of several nuclear receptor family members, the roles of RXRs in various neurological disorders remain relatively under-investigated. RXR acts as ligand-regulated transcription factor, modulating the expression of genes that plays a critical role in mediating several developmental, metabolic, and biochemical processes. Cumulative evidence indicates that abnormal RXR signalling affects neuronal stress and neuroinflammatory networks in several neuropathological conditions. Protective effects of targeting RXRs through pharmacological ligands have been established in various cell and animal models of neuronal injury including Alzheimer disease, Parkinson disease, glaucoma, multiple sclerosis, and stroke. This review summarises the existing knowledge about the roles of RXR, its interacting partners, and ligands in CNS disorders. Future research will determine the importance of structural and functional heterogeneity amongst various RXR isotypes as well as elucidate functional links between RXR homo- or heterodimers and specific physiological conditions to increase drug targeting efficiency in pathological conditions.

24 January 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMark S. Baker
Mark S. Baker
Seong Beom AhnSeong Beom Ahn
Seong Beom Ahn
Abidali MohamedaliAbidali Mohamedali
Abidali Mohamedali
MIMohammad T. Islam
Mohammad T. Islam
DCDavid Cantor
David Cantor
Shoba RanganathanShoba Ranganathan
Shoba Ranganathan
The Human Proteome Project aims to catalogue the ∼20,000 proteins encoded by the human genome. In this review, Baker et al. focus on the missing proteins, proteins that lack high stringency proteomic evidence, and launch MissingProteinPedia, a database aimed at accelerating the search for missing proteins.

28 August 2019 in Clinical Proteomics
Verified
Journal Article
Open access
PDF file
Seong Beom AhnSeong Beom Ahn
Seong Beom Ahn
SSSamridhi Sharma
Samridhi Sharma
Abidali MohamedaliAbidali Mohamedali
Abidali Mohamedali
SMSadia Mahboob
Sadia Mahboob
WRWilliam J. Redmond
William J. Redmond
MBMark S. Baker
Mark S. Baker
One of the most significant challenges in colorectal cancer (CRC) management is the use of compliant early stage population-based diagnostic tests as adjuncts to confirmatory colonoscopy. Despite the near curative nature of early clinical stage surgical resection, mortality remains unacceptably high—as the majority of patients diagnosed by faecal haemoglobin followed by colonoscopy occur at latter stages. Additionally, current population-based screens reliant on fecal occult blood test (FOBT) have low compliance (~ 40%) and tests suffer low sensitivities. Therefore, blood-based diagnostic tests offer survival benefits from their higher compliance (≥ 97%), if they can at least match the sensitivity and specificity of FOBTs. However, discovery of low abundance plasma biomarkers is difficult due to occupancy of a high percentage of proteomic discovery space by many high abundance plasma proteins (e.g., human serum albumin). A combination of high abundance protein ultradepletion (e.g., MARS-14 and an in-house IgY depletion columns) strategies, extensive peptide fractionation methods (SCX, SAX, High pH and SEC) and SWATH-MS were utilized to uncover protein biomarkers from a cohort of 100 plasma samples (i.e., pools of 20 healthy and 20 stages I–IV CRC plasmas). The differentially expressed proteins were analyzed using ANOVA and pairwise t-tests (p < 0.05; fold-change > 1.5), and further examined with a neural network classification method using in silico augmented 5000 patient datasets. Ultradepletion combined with peptide fractionation allowed for the identification of a total of 513 plasma proteins, 8 of which had not been previously reported in human plasma (based on PeptideAtlas database). SWATH-MS analysis revealed 37 protein biomarker candidates that exhibited differential expression across CRC stages compared to healthy controls. Of those, 7 candidates (CST3, GPX3, CFD, MRC1, COMP, PON1 and ADAMDEC1) were validated using Western blotting and/or ELISA. The neural network classification narrowed down candidate biomarkers to 5 proteins (SAA2, APCS, APOA4, F2 and AMBP) that had maintained accuracy which could discern early (I/II) from late (III/IV) stage CRC. MS-based proteomics in combination with ultradepletion strategies have an immense potential of identifying diagnostic protein biosignature.

1 March 2022 in Survey of Ophthalmology
Verified
Journal Article
Closed access
SSSamridhi Sharma
Samridhi Sharma
NCNitin Chitranshi
Nitin Chitranshi
RWRoshana Vander Wall
Roshana Vander Wall
DBDevaraj Basavarajappa
Devaraj Basavarajappa
Vivek GuptaVivek Gupta
Vivek Gupta
YYYuyi You
Yuyi You

21 November 2014 in Scientific Reports
Verified
Journal Article
Open access
SSSamridhi Sharma
Samridhi Sharma
SRSandipan Ray
Sandipan Ray
AMAliasgar Moiyadi
Aliasgar Moiyadi
ESEpari Sridhar
Epari Sridhar
Sanjeeva SrivastavaSanjeeva Srivastava
Sanjeeva Srivastava
Meningiomas are the most common non-glial tumors of the brain and spine. Pathophysiology and definite histological grading of meningiomas are frequently found to be deceptive due to their unusual morphological features and locations. Here for the first time we report a comprehensive serum proteomic analysis of different grades of meningiomas by using multiple quantitative proteomic and immunoassay-based approaches to obtain mechanistic insights about disease pathogenesis and identify grade specific protein signatures. In silico functional analysis revealed modulation of different vital physiological pathways including complement and coagulation cascades, metabolism of lipids and lipoproteins, immune signaling, cell growth and apoptosis and integrin signaling in meningiomas. ROC curve analysis demonstrated apolipoprotein E and A-I and hemopexin as efficient predictors for meningiomas. Identified proteins like vimentin, alpha-2-macroglobulin, apolipoprotein B and A-I and antithrombin-III, which exhibited a sequential increase in different malignancy grades of meningiomas, could serve as potential predictive markers.

21 November 2014 in Proteomics
Verified
Journal Article
Closed access
PDF file
SSSamridhi Sharma
Samridhi Sharma
SRSandipan Ray
Sandipan Ray
Shuvolina MukherjeeShuvolina Mukherjee
Shuvolina Mukherjee
AMAliasgar Moiyadi
Aliasgar Moiyadi
ESEpari Sridhar
Epari Sridhar
Sanjeeva SrivastavaSanjeeva Srivastava
Sanjeeva Srivastava